Monitor regulatory approval timelines and the upcoming shareholder vote, as these are key milestones for deal closure. The significant premium suggests strong strategic value, but integration risks and potential antitrust scrutiny should be watched.
Price Chart
Executive Summary
Organon & Co. has entered into a definitive merger agreement with Sun Pharmaceutical, under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in cash, representing a 103% premium. The deal values Organon at an enterprise value of $11.75 billion and is subject to regulatory approvals and shareholder vote. Concurrently, Organon appointed Joseph Morrissey as permanent CEO and Carrie Cox as Executive Chair on a non-interim basis.
Key Financial Metrics
Key Facts
- Sun Pharmaceutical will acquire Organon for $14.00 per share in cash, a 103% premium to the unaffected trading price.
- The transaction has an enterprise value of $11.75 billion.
- The deal is expected to close in early 2027, subject to regulatory approvals and Organon shareholder approval.
- Joseph Morrissey was appointed as permanent CEO, and Carrie Cox as Executive Chair on a non-interim basis.
- The merger agreement includes a $120 million termination fee if Organon accepts a superior proposal.
Financial Impact
The acquisition values Organon at an enterprise value of $11.75 billion, with shareholders receiving $14.00 per share in cash.
Risk Factors
- Regulatory approvals may be delayed or denied, particularly from antitrust authorities.
- Organon shareholders may not approve the merger, especially if a superior offer emerges.
- Integration challenges could impact the combined company's performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-178718 |
| Document: d38652d8k.htm | 0001193125-26-178718 |
| Document: d38652dex991.htm | 0001193125-26-178718 |
| Document: 0001193125-26-178718-index-headers.html | 0001193125-26-178718 |
| Document: 0001193125-26-178718-index.html | 0001193125-26-178718 |
| Document: 0001193125-26-178718.txt | 0001193125-26-178718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 10w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.78 (−0.73%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.78 (−1.70%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.78 (+2.15%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.78 (+2.68%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.78 (+2.45%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.78 (+3.11%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.78 (+4.04%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.78 (−4.04%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.78 (+3.49%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.78 (+3.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers